Five things for pharma marketers to know:
- InCarda Therapeutics stopped its Phase 3 trial for its arrhythmia drug FlecIH-103 due to “limited efficacy upon blinded review.”
- Telehealth company Ro halted advertising of Novo Nordisk’s obesity drug Wegovy amid shortages.
- Staff at the Food and Drug Administration staff said new COVID-19 boosters for this fall should be tweaked to target XBB Omicron subvariants, like XBB.1.5 or XBB.2.3.
- 23andMe announced that it is restructuring and plans to cut 75 jobs.
- Doctors have begun using ChatGPT to help craft messages to patients in more empathetic and compassionate ways.
